B
BioAffinity Technologies
A cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases
About BioAffinity Technologies
BioAffinity Technologies is a biotechnology company focused on developing non-invasive diagnostics and targeted therapeutics for early-stage cancer detection and treatment. Operating in the healthcare and medical research market, the company serves patients, healthcare providers, and research institutions. BioAffinity Technologies utilizes advanced scientific research and innovative techniques, such as porphyrin molecules that bind to cancer cells and fluoresce to distinguish them from non-cancerous cells. The business model revolves around the development and commercialization of these diagnostic tools and treatments, generating revenue through product sales, partnerships, and licensing agreements. The company collaborates with institutions like the University of Texas Health Science Center to advance its research and product offerings.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- San Antonio, United States
- Listing
- IPO 2022
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Armistice Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioAffinity Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioAffinity Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.